XNAS
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | — | -0.76 | — | $0 | — | -0.94% | -5.66% | — |
| 2026-03-30 | Q4 2025 | -0.38 | -0.19 | +50.00% | $1.0M | ✅ Beat | -0.35% | +187.20% | +129.76% |
| 2025-11-12 |
| Q3 2025 |
| — |
| -0.30 |
| — |
| $875,000 |
| — |
| — |
| — |
| — |
| 2025-08-05 | Q2 2025 | — | -0.11 | — | $96,000 | — | -9.92% | -16.95% | -17.30% |
| 2025-03-04 | Q4 2024 | — | 0.22 | — | $1.8M | — | -7.98% | -2.47% | -1.90% |
| 2024-11-14 | Q3 2024 | — | -0.29 | — | $194,000 | — | +45.76% | -19.77% | +99.44% |
| 2024-08-07 | Q2 2024 | — | -0.53 | — | $0 | — | +0.07% | -4.24% | -2.91% |
| 2024-05-07 | Q1 2024 | — | -0.62 | — | $0 | — | +0.99% | +1.41% | -6.69% |
Showing last 8 quarters.